Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

21-40 of 306 trials

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPediatrics

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visits Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Richter Syndrome: GLOfitamab with Chemotherapy

We are studying a new treatment combining GLOfitamab with standard chemotherapy for patients with Richter syndrome. The goal is to see if this combination improves treatment response and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesHematologyOncology

Triple-Negative Breast Cancer: Tiragolumab and Atezolizumab with Chemotherapy

We are studying a combination of two immunotherapy drugs with chemotherapy for patients with triple-negative breast cancer. This trial aims to evaluate the treatment's effectiveness and safety in both early and advanced stages of the disease.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost ReimbursementHematologyNephrology

Systemic Lupus Erythematosus: ESK-001 Treatment Study

We are investigating a new medication, ESK-001, for adults with systemic lupus erythematosus to see if it helps improve disease activity and is safe to use. Participants will receive either ESK-001 or a placebo in this study.

Systemic Lupus Erythematosus1-2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Bladder Cancer Treatment: Chemoablation vs. Standard Care

We are studying whether a new chemoablation method is more effective than standard bladder surgery and chemotherapy for patients with recurrent non-muscle invasive bladder cancer. This may help reduce recurrence rates and improve long-term outcomes.

Recurrent Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Cost ReimbursementOncologyUrology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyInternal Medicine

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits No Placebo Investigational MedicinesHematologyOncology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesInternal MedicineOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy

We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Cutaneous T-cell LymphomaMycosis Fungoides and Sézary Syndrome>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesOncology

Asthma Treatment: Povorcitinib Study

We are evaluating a new medication for adults with moderate to severe asthma that isn't well controlled. The study aims to see if it improves lung function and reduces asthma attacks.

Asthma3-6 monthsEfficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemotePulmonology

Nipocalimab for Pregnancies at Risk of Severe Hemolytic Disease

We are studying whether Nipocalimab can help reduce the risk of fetal anemia in pregnant individuals at risk for severe hemolytic disease of the fetus and newborn. This trial compares the treatment to a placebo to assess its effectiveness.

Hemolytic Disease of the Fetus and Newborn>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsInfectious Diseases

Relapsed/Refractory AML: Venetoclax and Decitabine Therapy

We are studying a new combination treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to see if this therapy can help achieve remission and improve safety and recovery outcomes.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesHematologyOncology

HIV-1 Treatment: Long-Acting Cabotegravir and Rilpivirine for Older Adults

We are studying a new long-acting treatment for people aged 60 and older living with HIV-1. The goal is to see if it effectively controls the virus and how it affects overall health.

HIV-1>2 yearsMonitoring phase (IV)11-15 visits No Placebo Investigational MedicinesInfectious DiseasesInternal Medicine

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visits Standard MedicinesNeurologyPsychiatry

Idiopathic Pulmonary Fibrosis: Axatilimab Study

We are testing a new medication, axatilimab, for people with idiopathic pulmonary fibrosis to see if it improves lung function and overall quality of life compared to a placebo.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Search Clinical Trials in the European Union